Crucell is developing an Ebola vaccine based on its proprietary adenoviral vectors and produced using its own PER.C6^® technology. This recombinant vaccine expresses Ebola viral proteins and provides protection against infection with the Ebola virus. For further information on this program please refer to our R&D section of the website or download the following documents.

• About Ebola (PDF)
• Developing an Ebola vaccine (PDF)

03 Oct. 2008: Crucell Receives NIAID/NIH Contract for Development of Ebola and Marburg Vaccines

26 Sept. 2006: Crucell and NIH VRC Announce Start of Ebola Vaccine Clinical Trial

29 April 2005: Single-shot Outbreak Vaccine Provides Full Protection Against Ebola According to Results of New Animal Studies

14 April 2005: Crucell and NIH sign € 21.4 million Ebola Vaccine Manufacturing Contract

18 Mar. 2005: Crucell Secures Exclusive Patent License from NIH to Commercialize Ebola Vaccines

17 Mar. 2005: Crucell and NIH extend Ebola Vaccine Agreement

1 June 2004: Crucell’s PER.C6^®-based Vaccine Protects Monkeys from Ebola

7 Aug. 2003: Ebola Vaccine Holds Promise for Protection in Humans

14 Oct. 2002: Crucell and the US National Institutes of Health Sign Contract for Production of Ebola, Marburg and Lassa Vaccines for Use in Human Clinical Trials

7 Aug. 2002: Crucell and NIH Extend Ebola Vaccine Agreement to include Marburg and Lassa Vaccines

16 May 2002: Crucell and NIH to develop Ebola vaccine

Publications related to Crucell’s Ebola vaccine program are listed below. Please click on any of these to access the abstracts of the articles. For more Crucell scientific papers please use search word ‘Crucell’ at PubMed, http://www.ncbi.nlm.nih.gov./entrez/query.fcgi.

Sullivan, NJ et al, Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates, Nature, 424, 681-684, (2003).

Visit Useful Links